These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29982641)

  • 1. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
    Whitfield MG; Warren RM; Mathys V; Scott L; De Vos E; Stevens W; Streicher EM; Groenen G; Sirgel FA; Van Rie A
    J Antimicrob Chemother; 2018 Oct; 73(10):2667-2674. PubMed ID: 29982641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed
    Wang W; Liu R; Yao C; Huo F; Shang Y; Zhang X; Wang Y; Xue Z; Ma L; Pang Y
    Microbiol Spectr; 2022 Feb; 10(1):e0208721. PubMed ID: 35107324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study.
    Mboowa G; Namaganda C; Ssengooba W
    BMC Infect Dis; 2014 Sep; 14():481. PubMed ID: 25190040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study.
    Ullah I; Shah AA; Basit A; Ali M; Khan A; Ullah U; Ihtesham M; Mehreen S; Mughal A; Javaid A
    BMC Infect Dis; 2016 Aug; 16():413. PubMed ID: 27519406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the
    Guo Y; Cao X; Yang J; Wu X; Liu Y; Wan B; Hu L; Wang H; Yu F
    J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33507146
    [No Abstract]   [Full Text] [Related]  

  • 6. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis.
    Jamieson FB; Guthrie JL; Neemuchwala A; Lastovetska O; Melano RG; Mehaffy C
    J Clin Microbiol; 2014 Jun; 52(6):2157-62. PubMed ID: 24740074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
    Cavusoglu C; Karaca-Derici Y; Bilgic A
    Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Impact of the
    Yu MC; Hung CS; Huang CK; Wang CH; Liang YC; Lin JC
    Microbiol Spectr; 2022 Aug; 10(4):e0075422. PubMed ID: 35924839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Tan Y; Hu Z; Zhao Y; Cai X; Luo C; Zou C; Liu X
    J Clin Microbiol; 2012 Jan; 50(1):81-5. PubMed ID: 22075601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?
    Schön T; Juréen P; Chryssanthou E; Giske CG; Kahlmeter G; Hoffner S; Angeby K
    J Antimicrob Chemother; 2013 Sep; 68(9):2074-7. PubMed ID: 23633684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay.
    Yoshida S; Suzuki K; Iwamoto T; Tsuyuguchi K; Tomita M; Okada M; Sakatani M
    J Infect Chemother; 2010 Oct; 16(5):360-3. PubMed ID: 20354890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia.
    Sintchenko V; Chew WK; Jelfs PJ; Gilbert GL
    Pathology; 1999 Aug; 31(3):257-60. PubMed ID: 10503273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
    Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
    J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmission of Mycobacterium tuberculosis presenting unusually high discordance between genotypic and phenotypic resistance to rifampicin in an endemic tuberculosis setting.
    Brandao AP; Pinhata JMW; Simonsen V; Oliveira RS; Ghisi KT; Rabello MCS; Fukasava S; Ferrazoli L
    Tuberculosis (Edinb); 2020 Dec; 125():102004. PubMed ID: 33017720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.